Targeted zinc-finger (ZF) DNA-binding domains in conjunction with nuclear receptor ligand-binding domains (LBDs) produce chemically inducible gene switches that have applications in gene therapy and proteomic and genomic research. The benzoate X receptor-b (BXRb) LBD was used to construct homodimer and single-chain ZF transcription factors (ZF TF s). These ZF TF s specifically regulated the transcription of target genes in response to two ligands, ethyl-4-hydroxybenzoate and propyl-4-hydroxybenzoate, in a dose-dependent manner. The ZF TF s also regulated the expression of endogenous intercellular adhesion molecule-1 in response to either ligand. The advantage of BXRb-based ZF TF s is that the ligands are inexpensive and easily synthetically modified, making the system a base for creation of orthogonal ligand-receptor pairs and expanding the gene-switch toolbox.
INTRODUCTION
Gene switches that allow control of transcription of a specific gene with small-molecule drugs are valuable tools for studying gene function and biological pathways, and may provide the basis for gene therapies. Tightly controlled, highly inducible and dose-responsive activation of transgenic and endogenous gene expression are required for effective and safe use of these gene switches. Zinc-finger (ZF)-based artificial transcription factors (TF ZF s), constructed by fusion of a ZF with an effector domain such as the herpes simplex VP16 domain (VP64) or the Krüppel-associated box (KRAB), 1 have been shown to regulate transcription of transgenic and endogenous genes. 2, 3 Using nuclear receptor ligand-binding domains (LBDs) as effector domains has the added desired elements of tunable exogenous and reversible control. [4] [5] [6] Selected ZF domains specifically recognize three bases of DNA. 7 ZFs are modular proteins that can be combined to create chains that recognize longer DNA sequences. [8] [9] [10] To date, ZF domains that recognized almost all of the GNN, ANN and CNN DNA triplets have been identified. [10] [11] [12] [13] [14] Approaches other than modular assembly also provide access to polydactyl ZF proteins. 15 Artificial transcription factors that use ZFs for DNA recognition typically use six ZFs to recognize 18 bases of DNA; this length of sequence is theoretically unique in the genome. 16 Nuclear receptors are ligand-activated transcription factors that regulate growth, development and homeostasis. Binding of smallmolecule ligands, including hormones, vitamins and dietary lipids, causes a conformational change in the LBD. This change allows binding to DNA and to co-activators, which recruit the transcription machinery, thereby activating transcription in a reversible liganddependent manner. Nuclear receptors function as homodimers or heterodimers with the retinoid X receptor (RXR). 17, 18 The modular nature of ZFs and nuclear receptor LBDs make them ideal partners for the construction of gene switches, and in early studies we reported the development of progesterone, estrogen and ecdysone receptor (EcR)-based ZF transcription factors (ZF TF s). 4 More recently, we reported using single-chain estrogen receptor homodimers and single-chain RXR/EcR heterodimers linked to six-finger ZFs to regulate endogenous gene transcription in a dosedependent manner. 6 In an alternative approach, Dent and coworkers used a truncated progesterone receptor and the nuclear factor-kB p65 activation domain linked to the VZ+434 ZF to create a smallmolecule-activated gene switch that relies on translocation of the protein to the nucleus after ligand binding. 5 Here, we report a new tool for the gene-switch toolbox that uses the benzoate X receptor-b (BXRb) as a gene switch. The BXRb from Xenopus laevis is a member of the nuclear receptor superfamily of ligand-activated transcription factors. It is closely related to Xenopus BXRa, mouse pregnane X receptor and human steroid and xenobiotic X receptor. 19 However, BXRb does not function as a xenobiotic receptor as do pregnane X receptor and steroid and xenobiotic X receptor 20 and is less promiscuous than BXRa in both ligand and co-activator preferences. 21 BXRb functions endogenously as a heterodimer with RXRa 19 but has shown to function as a homodimer in transient transfection assays. 20, 21 BXRb's chief advantage over other nuclear receptors used as ligandactivated gene switches is its ligands. Ligands for other nuclear receptor used in gene switches include tamoxifen, mifepristone and ponasterone-A. 5, 6 These compounds are expensive and, with the exception of ponasterone-A, have biological activity in humans. The ligands for BXRb, ethyl-4-hydroxybenzoate (E-4HB) and propyl-4-hydroxybenzoate (P-4HB), are benzoates and are commonly known as parabens. These parabens are generally regarded as safe and are used as preservatives in cosmetics and pharmaceuticals. Other than weak estrogenic activity (these parabens are 410 000-fold less potent than 17b-estradiol), neither E-4HB nor P-4HB has known biological activity and neither are carcinogenic nor teratogenic. 22 E-4HB nor P-4HB are small and inexpensive. Additionally, as benzoates are easily synthetically modified, the parabens lend themselves to combinatorial chemistry and can be paired with libraries of BXRb mutants to create new orthogonal ligand-receptor pairs or increase affinity of the currently recognized ligands. These techniques have been demonstrated for RXR and estrogen receptor-based gene switches. 23, 24 Here, we fused ZFs with BXRb to create a versatile geneswitch platform. The TF ZF s described have potential for use in gene therapy and for the study of gene expression and biological pathways.
RESULTS AND DISCUSSION
Three systems were constructed to study BXRb-based TF ZF s. First, the BXRb linker and LBD were fused directly to three-finger ZF proteins, C7 (ref. 25) and N1 (ref. 4) (Figure 1 , upper panel). C7 is based on the Zif268 and has a K d of 0.5 nM for its DNA target, whereas N1 is based on SP1C and has a K d between 5 and 10 mM. Using ZFs with different affinities allowed us to investigate the effect that ZF affinity for DNA target has on inducible expression. Previous versions of ZF-nuclear receptor fusions have used VP64 to impart greater transcriptional activation; 4 however, in the BXR system, VP64 fusions demonstrated unacceptable levels of activation in the absence of ligand (data not shown).
Inducible transgene expression was probed using a luciferase reporter vector with 10 copies of the respective ZF response elements repeated with 4 bp spacing upstream of the luciferase gene. HeLa cells were transiently transfected with three plasmids carrying the BXRb ZF TF , the reporter and a constitutively expressed b-galactosidase gene (CMV-LacZ) for normalization of transfection efficiency. Serial dilutions of each ligand (E-4HB and P-4HB) and 0.1% dimethyl sulfoxide (as a control) were added B24 h after transfection, and cell lysates were prepared 48 h after transfection.
BXRb is able to function in human cells as a homodimer ( Figure 2 ). When fused to either ZF, BXRb showed a dose-dependent activation of gene expression, with virtually no background expression in the absence of ligand. In general, use of P-4HB resulted in higher absolute expression levels than E-4HB, although the fold upregulations were comparable ( Figure 2 and Table 1 ). The EC 50 s (concentration of ligand at which relative light unit is half maximal) for both ZFs with P-4HB (1-3 mM) were lower than with E-4HB (3-10 mM). Finally, the absolute and relative expression levels with C7 were higher than those with N1, reflecting the ZF affinity difference.
This homodimer system has its limits for practical use. The direct repeat response elements with four-base spacing are required for proper dimerization of the BXRb LBDs to occur. This requirement severely limits the endogenous target sites available for transcriptional activation. Therefore, we developed systems with a single-chain BXRb homodimer (BLB) and a single-chain RXRa-BXRb heterodimer (RLB) as shown in Figure 1 , middle and lower panels. These constructs can be linked to a six-finger ZF protein, removing the symmetry requirement and increasing the targeting selectivity.
The single-chain constructs consisted of a six-finger ZF, followed by the linker and the LBD from either BXRb or RXRa. These were linked by a 30 amino-acid flexible linker to the LBD of BXRb. Constructs with and without a VP64 domain were also made for comparison ( Figure 1 , middle and lower panels). The CD54-31opt ZF (31opt), which targets the promoter for intercellular adhesion molecule-1 (ICAM-1), was chosen for these studies because it binds with high affinity and specificity to a single unique site of the ICAM-1 promoter 26 and can be used for studying both transgene and endogenous regulation. The 31opt-BLB, 31opt-RLB, 31opt-BLB-VP64 and 31opt-RLB-VP64 vectors were transiently transfected with a reporter plasmid containing the ICAM-1 promoter upstream of the luciferase gene 26 and the CMV-LacZ plasmid. The ligands were added, and the luciferase assay was performed as described for the C7-and N1-BXRb constructs. In contrast to the reporter used for the homodimer system studied with C7-and N1-BXRb constructs, this reporter contains only a single response element.
BLB and RLB both showed dose-dependent transcriptional activation with and without the VP64 domain ( Figure 3 ). The constructs with VP64 imparted a higher absolute level of activation, but the fold activation was less than without VP64 (Table 1) . There was more basal activation with RLB than BLB. We hypothesize that by linking RXR and BXR in the RLB construct their affinity for each other allows dimerization, even when ligand is not present (BXRb forms a heterodimer with RXRa). As BXRb does not naturally form homodimers, there was less basal activation of transcription. The BLB and RLB constructs were tested for their ability to upregulate transcription of endogenous ICAM-1. When the VP64 domain was present, endogenous activation was observed, and the addition of the ligand induced little (BLB) or no (RLB) additional upregulation (data not shown). When the VP64 domain was not present, the 15-25% of cells transduced with the RLB or BLB constructs showed 25-to 50-fold induction (shift in mean fluorescence intensity) of ICAM-1 expression in the presence of 100 mM E-4HB or P-4HB (Figure 4) . Controls with no ligand, or with nontargeting ZFs (data not shown), did not show any induction of expression. This demonstrated that, in the presence of their ligands, the BLB and RLB constructs induced expression of endogenous genes by targeting the endogenous promoter.
For the estrogen receptor (scER) and RXR/EcR (RE and RLE) single-chain gene switches, endogenous regulation is context dependent. 6 In the BLB and RLB systems, only a fraction of cells showed upregulation of ICAM-1 expression; this could be due to interaction with retinoic acid receptor as was hypothesized with the RE and RLE switches. Additionally, the ICAM-1 promoter is known to contain a silencing region that regulates endogenous expression 27 and this may counteract the upregulation by BLB and RLB in a subpopulation of the C8161 cells. However, for the cells that do respond to ligand, the 25-to 50-fold induction of ICAM-1 expression is much greater than the maximum 4.8-fold induction seen with our previously published TF ZF s. 6 The basal upregulation of the target genes in the reporter and endogenous systems when BLB and BLR are fused to VP64 may stem from BXRb's non-human origin. Nuclear receptors naturally interact with corepressors, which function to repress transcription when no ligand is bound. 28 BXRb may not interact properly with human corepressors, which is a limitation of this system. The RE, RLE and scER TF ZF s are of human origin and do not have this issue, and are therefore able to utilize VP64 and KRAB to assist in the up-and downregulation of gene expression. In conclusion, we have demonstrated that BXRb can function, in conjunction with ZFs, as a gene switch in the context of reporter plasmids and endogenous genes. These BLB and RLB ZF TF s complement the previously described nuclear receptor-based gene switches 5, 6 by providing a system activated by small, inexpensive ligands. The BLB and RLB ZF TF systems can be readily adapted through engineering of the BXR LBD to bind derivatives of the known ligands as has been previously done with RXR. 24 A library of BXR/ligand gene switches paired with a multitude of ZFs has the potential to be a very powerful tool for genomic and proteomic research, as well as gene therapy applications.
MATERIALS AND METHODS

Plasmid construction
BXRb was codon optimized for human expression and synthesized by GeneArt (Regensburg, Germany). The DNA sequence and translation for BXRb are included as Supplementary Information. The Supplementary Information also includes DNA sequences for the effector plasmids and translations of the effectors. All restriction endonucleases were purchased from New England Biolabs (Ipswich, MA, USA) with the exception of SfiI, which was purchased from Roche (Indianapolis, IN, USA). pcDNA3-N1-BXR and pcDNA3-C7-BXR were created by first inserting BXR between E2C and VP64 in the pcDNA3/ E2C-V64 (ref. 8) plasmid via digestion with FseI and AscI. The VP64 domain was removed by digesting with AscI and NotI, followed by filling in the overhangs using T4 DNA polymerase and blunt ligation. A stop codon was added using site-directed mutagenesis with primers BXRstopF (5¢-GTGTTCGGATCCCTG AACGAGTGAGGGCGCGGGCCGC-3¢) and BXRstopR (5¢-GCGGCCCGCGC CCTCACTCGTTCAGGGATCCGAACAC-3¢). The E2C ZF was replaced with ZFs N1 (ref. 8) and C7 (ref. 25) via SfiI digestion. To construct pcDNA3-31opt-RLB-VP64, an NheI site was added in the linker of pcDNA3/E2C-RLE-VP64 via overlap extension PCR. First, the RXRa portion was amplified with primers pcDNAseqF (5¢-CACTATAGGGAGACCCAAGCTTG-3¢) and NheI+R (5¢-GCC ACCGCCGCTAGCGGAACCACCCCCACCAC-3¢), and the EcR portion was amplified with primers NheI+F (5¢-GTGGTGGGGGTGGTTCCGCTAGCGGC GGTGGC-3¢) and Primseq2 (5¢-CAGATGGCTGGCAACTAG-3¢). The PCR products were then annealed and amplified in a PCR reaction with pcDNAseqF and Primseq2. This PCR product was digested with AscI and AgeI and ligated into pcDNA-E2C-BXR-VP64, replacing the BXR region and creating pcDNA-E2C-RLE(+NheI)-VP64. BXR was amplified from pcDNA-N1-BXR-VP64 with primers LinkBXRF (5¢-GAGGAGGAGGCTAGCGGCGGTGGCGGTGGCTCC TCTGGTGGCGGTGGCGGTTCTTCCCCCGAGCAGCAGCACTTC-3¢) and BXRR (5¢-GAGGAGGAGGGCGCGCCCCTCG-3¢). The PCR product was digested with NheI and AscI and used to replace the EcR in pcDNA-E2C-RLE(+NheI)-VP64. The E2C ZF was replaced with the CD54-31opt 26 ZF. To construct pcDNA3-31opt-BLB-VP64, BXR was amplified from pcDNA-N1-BXR-VP64 with primers BXRF (5¢-GAGGAGGAGGGCCGGCCGGAAGG-3¢) and LinkBXRR (5¢-GAGGAGGAGGCTAGCGGAACCACCCCCACCACCGCC CGAGCCACCGCCCGAGCCACCGCCACCAGAGAACTCGTTCAGGCTGCC GAAC-3¢). The PCR product was digested with FseI and NheI, and used to replace the RXR region in pcDNA3-31opt-RLB-VP64. To construct pcDNA3-31opt-RLB and pcDNA3-31opt-BLB, BXR was amplified from pcDNA-N1-BXR with LinkBXRF and BXRSacIIR (5¢-GAGGAGGAGCCGCGGCCCG CGC-3¢). The PCR product was digested with NheI and SacII, and used to replace BXR-VP64 in pcDNA3-31opt-RLB-VP64 and pcDNA3-31opt-BLB-VP64. 31opt-BLB-VP64 was transferred into the pMX-IRES-GFP vector via digestion with XhoI and PacI and subsequently ligated into pMX-E2C-VP64 (ref. 6) to create pMX-31opt-BLB-VP64. pMX-31opt-RLB-VP64 was created by digestion of pcDNA3-31opt-RLB-VP64 with XcmI and ligation into pMX-31opt-BLB-VP64, replacing the first BXR with RXR. The pMX-31opt-RLB-KRAB and pMX-31opt-BLB-KRAB plasmids were created by digestion of pMX-E2C-RLE-KRAB 6 with AscI and EcoRI. The resulting fragment was used to replace the VP64 domains of pMX-31opt-RLB-VP64 and pMX-31opt-BLB-VP64 with KRAB. The pMX-31opt-BLB and pMX-31opt-RLB plasmids were created by digestion of and pMX-31opt-BLB-KRAB and pMX-31opt-RLB-KRAB with AscI and EcoRI, followed by ligation with a small, double-stranded DNA adaptor (5¢-CGCGCCGATGCTTACCCGTACGACGTTCCGGACTACGCTTC TTGAATCGGTAGG-3¢).
Luciferase assays E-4HB and P-4HB were purchased from Sigma (St Louis, MO, USA). HeLa cervix carcinoma cells were obtained from the ATCC (Manassas, VA, USA) and were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum, antibiotics and antimycotics. Approximately 5Â10 4 HeLa cells were seeded into 24-well plates at 40-60% confluency. HeLa cells were transfected with 150 ng reporter plasmid (pGL3-10xN1-TATA 8 , pGL3-10xC7-TATA 8 or pGL3-ICAM-1 (ref. 26) ), 25 ng effector plasmid (pcDNA3-C7-BXRb, pcDNA3-N1-BXRb, pcDNA3-31opt-RLB, pcDNA3-31opt-BLB, pcDNA3-31opt-RLB-VP64 or pcDNA3-31opt-BLB-VP64) and 100 ng of CMV-LacZ using Lipofectamine and Plus reagents (Invitrogen, Carlsbad, CA, USA). After B24 h, expression was induced by the addition of serial dilutions of E-4HB or P-4HB. Cell lysates were prepared B48 h after transfection by incubation in Passive Lysis Buffer (Promega, Madison, WI, USA). Luciferase and b-galactosidase activities were measured using assay reagent kits from Promega and Tropix (Bedford, MA, USA), respectively, in a MicroLumat LB96P luminometer (EG&G Berthold, Gaithersburg, MD, USA). Luciferase activity was normalized to b-galactosidase activity in HeLa cells.
Endogenous activation of ICAM-1
The 293-GagPol packaging cell line was obtained from I Verma (Salk Institute, San Diego, CA, USA). Melanoma C8161 cells were a gift from RA Reisfeld (Scripps Research Institute, La Jolla, CA, USA) and were chosen because they express ICAM-1 at moderate levels. 293-GagPol cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal calf serum, antibiotics and antimycotics. C8161 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, antibiotics, antimycotics, 1 mM modified Eagle's medium sodium pyruvate and 20 mM HEPES. Retroviral gene delivery was accomplished as previously described 26 with minor modifications. Virus was cleared by filtration with a 0.45-mm syringe filter, and C8161 host cells were infected three times with media from virus expressing 293-GagPol cells. After 24 h, Dulbecco's modified Eagle's medium media (as described above for C8161 cell maintenance) additionally supplemented with 100 mM E-4HB, 100 mM P-4HB or 0.1% dimethyl sulfoxide (as vehicle) was added. Dimethyl sulfoxide was used as a cosolvent at 1 ml ml À1 vol/vol. After 24 h, cell-surface expression of ICAM-1 was measured with an anti-ICAM-1 antibody (clone HA58, BD Pharmingen, San Diego, CA, USA) at 5 mg ml À1 . Mouse IgG2a-UNLB (Southern Biotechnology Associates, Birmingham, AL, USA) was used as an isotype control at 2.5 mg ml À1 , and Cy-5-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, USA) diluted 1:1000 was used as the secondary antibody. Flow cytometric data were collected on an LSRII (BD Pharmingen) and analyzed using FlowJo (Tree Star Inc., Ashland, OR, USA; http://www.flowjo.com).
